Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 38 - Medicinal preparations containing peptides
Patents for A61K 38 - Medicinal preparations containing peptides (316,240)
06/2003
06/10/2003US6576638 Use of substance P antagonists in the treatment of the adenocarcinomas
06/10/2003US6576618 Cholesterol containing cationic liposome having gene encoding insulin like growth factor I
06/10/2003US6576613 Title inhibitors of urokinase
06/10/2003US6576611 Methods of reducing atrophy or dysfunction of gut-associated lymphoid tissue
06/10/2003US6576610 Includes substructure with thrombogenic potential operably linked to selective recognition domain; interacts with function forming context expressed by cells or tissues
06/10/2003US6576609 Methods and compositions for generating angiostatin
06/10/2003US6576608 Stimulating tyrosine phosphorylation of Flt4 tyrosine kinase receptor in Flt4-expressing cell
06/10/2003US6576607 Methods using CNS neurite outgrowth modulators
06/10/2003US6576467 Methods for producing recombined antibodies
06/10/2003US6576465 Human bone accessory cells
06/10/2003US6576464 Methods for providing differentiated stem cells
06/10/2003US6576445 Chemokine α-4
06/10/2003US6576444 IRAK3 polynucleotides
06/10/2003US6576440 Treating a wound with an invasion inducing agent such as peptides containing PHSRN sequence
06/10/2003US6576437 Stimulus-inducible protein kinase complex and methods of use therefor
06/10/2003US6576434 Transport protein of given amino acid sequence; exposing cells that express the protein to compound; measuring ion transport; use in treatment of interleukin mediated atopic allergy, asthma and cystic fibrosis
06/10/2003US6576431 Treatment for myocardial infarction; enhancing clot lysis
06/10/2003US6576427 Human cartilage glycoprotein
06/10/2003US6576417 Synthetic antigens for the detection of antibodies to hepatitis C virus
06/10/2003US6576264 Insoluble drug delivery
06/10/2003US6576245 Primary package containing aqueous solution for parenteral administration comprising low molecular weight peptide-based thrombin inhibitor or salt,and having specified pH, sealed with rubber stopper or plunger containing bromobutyl rubber
06/10/2003US6576240 Antigenic structural peptide, antigenic and immunogenic compounds, and uses for detecting, preventing and treating an HCV infection
06/10/2003US6576238 Isolated protein selected from protein having specified amino acid sequence, or protein comprising homologue of flea protein comprising portion of specified amino acid sequence, which elicits antibody response against flea protein
06/10/2003US6576237 Vertebrate tissue pattern-inducing proteins, and uses related thereto
06/10/2003US6576236 Contacting T cell which expresses cytokine receptor gamma chain with anti-gamma chain antibody which binds to and transduces signal via gamma chain such that T cell responsiveness is stimulated
06/10/2003US6576235 Conjugate of purified uricase, retaining at least about 75% of uricolytic activity of unconjugated uricase and reduced in immunogenicity, in which each subunit of uricase is covalently linked to 2 to 10 strands of polyoxyethylene glycol
06/10/2003US6576232 Composition comprising mutant human interleukin 13 molecule comprising polypeptide having specified amino acid sequence
06/10/2003US6576231 Methods for treating HIV-Infected Patients by the Administration of GM-CSF and a protease inhibitor
06/10/2003US6576226 Local delivery of agents for disruption and inhibition of bacterial biofilm for treatment of periodontal disease
06/10/2003US6576218 Transplacental delivery of oligonucleotides
06/10/2003CA2191795C Antisense oligonucleotide modulation of raf gene expression
06/10/2003CA2166367C Live recombinant avian vaccine using an avian herpesvirus as vector
06/10/2003CA2143416C Inhibitor of collagen-stimulated platelet aggregation
06/10/2003CA2112697C Somatotropin for increasing reproductive performance of cattle
06/10/2003CA2107340C Monoclonal antibodies against human tnf-binding protein i (tnf-bp i)
06/10/2003CA2076652C Methods and compositions for the identification, characterization and inhibition of farnesyl protein transferase
06/10/2003CA2073554C Water-soluble composition for sustained-release
06/10/2003CA2071757C Implant compositions containing a biologically active protein, peptide or polypeptide
06/10/2003CA2065553C Stabilized factor viii preparations
06/10/2003CA2055670C Retroviral protease inhibiting compounds
06/07/2003CA2376719A1 A method to improve the safety of gene therapy
06/05/2003WO2003046581A2 Methods for diagnosis and treatment of epithelial-derived cancers,such as colorectal cancers and kidney cancers
06/05/2003WO2003046578A2 Method for the assessment and prognosis of sarcoidosis
06/05/2003WO2003046570A2 Glycoprotein and apolipoprotein biopolymer markers predictive of alzheimers disease
06/05/2003WO2003046560A2 Self-assembly molecules
06/05/2003WO2003046196A1 Secreted proteins
06/05/2003WO2003046187A1 Method for producing a recombinant polypeptide
06/05/2003WO2003046179A2 G-protein coupled receptor lustr2 and uses thereof
06/05/2003WO2003046176A2 Protein-protein interactions in human immunodeficiency virus
06/05/2003WO2003046171A1 A method for combined sequential agent delivery and electroporation for cell structures and use thereof
06/05/2003WO2003046170A1 A method for combined parallel agent delivery and electroporation for cell structures and use thereof
06/05/2003WO2003046165A1 Regulation of human aldose reductase-like protein
06/05/2003WO2003046164A1 Regulation of human prolyl 4-hydroxylase
06/05/2003WO2003046151A2 Nucleic acid-associated proteins
06/05/2003WO2003046150A2 Glycoprotein remodeling using endoglycanases
06/05/2003WO2003046147A2 Novel human g-protein coupled receptor, hgprbmy31, and variants and methods of use thereof
06/05/2003WO2003046145A2 Materials and methods for making improved liposome compositions
06/05/2003WO2003046137A2 Hiv envelope v3-ccr5 binding site immunogen
06/05/2003WO2003046132A2 Antisense modulation of myd88 expression
06/05/2003WO2003046127A2 Tumor endothelial marker 5 molecules and uses thereof
06/05/2003WO2003046013A1 Fusion protein having enhanced in vivo activity of erythropoietin
06/05/2003WO2003046007A2 Treatment of micro-organism infection
06/05/2003WO2003046003A2 Plasma protease c1 biopolymer markers predictive of alzheimers disease
06/05/2003WO2003045999A2 Human vanilloid receptor protein and polynucleotide sequence encoding same
06/05/2003WO2003045997A2 Fusion proteins containing tlp peptides
06/05/2003WO2003045991A2 Complement c3 precursor biopolymer markers predictive of alzheimers disease
06/05/2003WO2003045987A2 A food grade lantibiotic from streptococcus macedonicus and uses thereof
06/05/2003WO2003045982A1 Antibiotics fki-9739 and process for producing the same
06/05/2003WO2003045981A2 Concentrating aqueous fractions of lisinopril by reverse osmosis
06/05/2003WO2003045980A2 Glycopeptide remodeling using amidases
06/05/2003WO2003045978A2 Antagonist anti-cd40 monoclonal antibody therapy for multiple sclerosis treatment
06/05/2003WO2003045976A2 Use of antimicrobial proteins and peptides for the treatment of otitis media and paranasal sinusitis
06/05/2003WO2003045974A2 Methods and compositions for derepression of iap-inhibited caspase
06/05/2003WO2003045973A2 Peptides with growth inhibitory action
06/05/2003WO2003045970A1 Novel molecules of the card related protein family and uses thereof
06/05/2003WO2003045523A2 Therapeutic coating for an intravascular implant
06/05/2003WO2003045466A2 Catheter composition and uses thereof
06/05/2003WO2003045439A1 Genetic remedies for neurodegenerative diseases
06/05/2003WO2003045438A1 Increasing electro-gene transfer of nucleic acid molecules into host tissue
06/05/2003WO2003045434A2 Endothelin antagonists ina method and composition for potentiating an opiate analgesic
06/05/2003WO2003045430A1 Tnf-alpha inhibitors for the treatment of hepatic diseases
06/05/2003WO2003045426A1 T-cell epitodes in carboxypeptidase g2
06/05/2003WO2003045425A1 Muscle transcription factors
06/05/2003WO2003045424A1 Methods of compositions for normalizing lipid levels in mammalian tissues
06/05/2003WO2003045423A1 Erythropoietin dosing regimen for treating anemia
06/05/2003WO2003045422A1 Agonists and antagonists of prolixin for the treatment of metabolic disorders
06/05/2003WO2003045421A1 Agonists and antagonists of ryzn for the treatment of metabolic disorders
06/05/2003WO2003045420A2 Use of t-cell immune response cdna 7 (tirc7) for modulation of angiogenesis and/or neovascularization
06/05/2003WO2003045419A1 Injection solution comprising an lhrh antagonist
06/05/2003WO2003045418A1 Medicinal compositions for nasal absorption
06/05/2003WO2003045417A1 Antiglaucomatous agent and use thereof
06/05/2003WO2003045416A2 Antiphlogistic agent and the use thereof
06/05/2003WO2003045404A2 Treatment and diagnosis of diseases associated with adverse levels of zinc, cadmium and calcium
06/05/2003WO2003045380A1 Ilk inhibitors for the treatment of renal disease
06/05/2003WO2003045357A1 Oral pharmaceutical formulations comprising paclitaxel, derivatives and methods of administration thereof
06/05/2003WO2003045335A2 Stem cell screening and transplantation therapy for hiv infection
06/05/2003WO2003045334A2 Methods and compositions for ameliorating the undesirable effects of chemotherapy
06/05/2003WO2003045332A2 Methods and compositions for treating lesions of the respiratory epithelium
06/05/2003WO2003045330A2 Materials and methods for making improved micelle compositions
06/05/2003WO2003045325A2 Dopaminergic stimulatory factor
1 ... 1831 1832 1833 1834 1835 1836 1837 1838 1839 1840 1841 1842 1843 1844 1845 1846 1847 1848 1849 1850 1851 ... 3163